Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Cardiovascular Disease Rate Differs Between SLE Patients of Different Races, Ethnicities

Kurt Ullman  |  Issue: December 2017  |  December 18, 2017

Dr. Barbhaiya

Dr. Barbhaiya

A recent epidemiologic study of patients with systemic lupus erythematosus (SLE) investigated racial and ethnic differences in the risk for cardiovascular disease (CVD). Among SLE patients enrolled in Medicaid, the risk for myocardial infarction (MI) was lower in Hispanics and Asians compared with whites, and the risk of stroke was higher in blacks and Hispanics compared with whites.1

“The risk of CVD is known to be greatly elevated among SLE patients and is the major cause of death in SLE,” says Medha Barbhaiya, MD, MPH, an assistant attending physician at the Hospital for Special Surgery and an assistant professor at Weill Cornell Medical College in New York City. “It is also known that Hispanic, Asian and African Americans in the United States have higher incidence of SLE than whites, and often more severe disease. However, the role of patient race and ethnicity in relation to risk of CVD previously has not been well understood.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Study

The researchers used the Medicaid Analytic eXtract to identify patients between 18 and 65 years old with an SLE diagnosis and at least 12 months of continuous enrollment. The study ran from 2000–2010. The researchers followed the subjects from their SLE index date to their first CVD event, MI or stroke (if any), or death, dis­enrollment, loss to follow-up or end of the follow-up period. Of the 65,788 SLE patients enrolled, 93% were women, roughly 42% were black, 48% were white, 16% were Hispanic, 3% were Asian, and 1% were Native American/Alaskan Native. The mean follow-up time was 3.8 years.

CVD rates were highest among blacks, with an incidence rate (IR) of 10.57, and lowest among Asians, with an IR of 6.63. After multivariable adjustment, the risk of CVD events was elevated among blacks, with a hazard ratio (HR) of 1.14, compared with whites. When examining MI or stroke risk separately, Hispanics and Asians had a lower risk, with an HR of 0.61 and 0.57, respectively, compared with white SLE patients enrolled in Medicaid. Blacks and Hispanics had a higher risk for stroke than whites, with an HR of 1.31 and 1.22, respectively. Among all patients, the annual CVD event IR per 1,000 person-years measured 9.31. All rates came with a 95% CI.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A recent epidemiologic study of patients with SLE investigated racial and ethnic differences in the risk for cardiovascular disease.

A recent epidemiologic study of patients with SLE investigated racial and ethnic differences in the risk for cardiovascular disease.
Rawpixel.com / SHUTTERSTOCK.COM

The researchers also looked at a subgroup of patients with lupus-related nephritis. However, these results remained too underpowered to demonstrate an association in that group after multivariable adjustment.

“In this very large study of Medicaid SLE patients drawn from a nationwide sample, we found a 31% and 22% increased risk for stroke among black and Hispanic patients [respectively] when compared with white patients,” Dr. Barbhaiya says. “The risk of heart attack was lower among Hispanics and Asians (39% and 43%, respectively) and similar for blacks when compared with whites. Although blacks had increased rates of hypertension, and Asians as well as Hispanics had fewer CVD risk factors compared with whites, adjustment for these factors did not account for the risks demonstrated.”

Results Need Confirmation

Dr. Barbhaiya says these results must be confirmed in other data sets using other populations. Additionally, as a population-based study, its ability to address individual patient management remains limited.

However, this large, Medicaid-based study did include SLE patients of multiple races and ethnicities, and it reveals demographic differences in CVD risks among SLE patients that clinicians should know about.

“The results go against current thinking, but are largely consistent with studies in the general population showing a Hispanic and Asian paradox,” Dr. Barbhaiya says. “It is currently not clear whether there is some protective element … causing them to not have as many strokes and MIs, or whether this is an epidemiologic association. However, this is the first time it has been shown in SLE.”

In contrast, African Americans have increased CVD risk factors, leading to more heart disease. The higher event rates in this group indicate SLE may result in an additional disease burden.

“If the MI risk [difference] is confirmed, this may suggest certain races/ethnicities could undergo earlier screening and aggressive risk factor management,” says Dr. Barbhaiya. “Additionally, we did not look at age stratification in this study. Further research is needed to determine whether, for example, we should be screening for hypertension and cholesterol in younger blacks with SLE than suggested by current guidelines.”

The fact the study worked with such a large data sample—a decade of data on more than 65,000 SLE patients—bolsters its results. Sociodemographic factors, as well as CVD- and SLE-specific comorbidities, were available in the claims data. This allowed the researchers to fit several models looking for confounders and mediators that might have contributed to increased CVD deaths in these patients.

They did note there are limitations inherent in using Medicaid data, including using administrative case definitions to identify SLE prevalence and potential misclassifications of race/ethnicity. The researchers also couldn’t examine risks among those 65 years or older given dual enrollment in Medicare.

Look at Underlying Mechanism?

Dr. Barbhaiya says further research must look at underlying mechanisms to better understand how to best address these findings. For example, is there a genetic component or perhaps biomarker differences doctors could exploit? Until these questions are answered, how to intervene remains an open question.

“Increased understanding of how race and ethnicity in SLE influence cardiac disease risk may help us improve prevention strategies,” she says. “The goal is to identify patients at higher risk for cardiovascular disease early and enhance the management of CVD among SLE patients.”


Kurt Ullman has been a freelance writer for more than 30 years and a contributing writer to The Rheumatologist for 10 years.

Reference

  1. Barbhaiya M, Feldman CH, Guan H, et al. Race/ethnicity and cardiovascular events among patients with systemic lupus erythematosus. Arthritis Rheumatol. 2017 Sep;69(9):1823–1831.

Page: 1 2 3 | Multi-Page
Share: 

Filed under:ConditionsResearch RheumSystemic Lupus Erythematosus Tagged with:ACR JournalAmerican College of Rheumatology (ACR)Cardiovascular diseasecomorbiditiesethnicitiesheartHispanicLupusMyocardial infarctionoutcomepatient careraceResearchrheumatologistrheumatologyriskstrokestudySystemic lupus erythematosus

Related Articles

    Racial Bias Found in Pain Assessment, Management, Treatment Recommendations by Clinicians

    October 10, 2016

    When evaluating a patient’s pain, whether consciously or not, a doctor may allow mistaken beliefs to affect their interpretation of a patient’s symptoms and, thus, treatment decisions. Chad Zuber/shutterstock.com In the world of evidence-based medicine, basing diagnosis and treatment decisions on belief instead of data seems anachronistic. And yet … clinicians are human, and humans…

    Blacks, Asians at Higher Risk for Allopurinol-Related Skin Reactions

    September 8, 2016

    Blend Images/shutterstock.com Be careful when prescribing allo­purinol to black and Asian gout patients, a study newly advises. Black and Asian patients who take this ubiquitous, more-than-40-year-old medication are at much higher risk of certain serious skin reactions than are Caucasians or Hispanics. Compared with Caucasians, blacks who take allopurinol to lower blood urate levels have…

    Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus

    April 20, 2017

    WASHINGTON, D.C.—Experts at the 2016 ACR/ARHP Annual Meeting session, Systemic Lupus Erythematosus—Clinical Aspects and Treatment IV: Biomarkers, reported on a number of recent studies showing advancement in our understanding of the disease mechanisms underlying systemic lupus erythematosus (SLE) that place these patients at risk for cardiovascular disease (CVD) and other comorbidities. Mechanisms of CVD Risk…

    Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

    February 16, 2021

    joel bubble ben / shutterstock.com In a controlled, large-cohort, longi­tudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1  This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences